main_header@2x

Increase Success in Drug Discovery While Reducing Time and Cost with RepliGut®

ABOUT US

Altis Biosystems has created a next-generation in vitro platform that reduces the time and cost of developing safer, more effective drugs.

By replicating native human biology, the intestinal stem cell platform produces more accurate and reproducible data for better clinical trial performance and reduces the need for animal testing.

home_img1_mob

PLATFORM

The RepliGut® Platform

RepliGut® is a unique, stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.

With a scalable platform, actionable data, high throughput screening to test thousands of compounds, and an unrivaled biobank, RepliGut® is the future of in vitro testing during drug development.

SERVICES

The RepliGut® is a reproducible and scalable platform that is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.

home_icon1

Intestinal Barrier Function

Maintains barrier integrity with high TEER values

Inflammatory Response

Inflammatory Response

Comprised of polarized intestinal cells grown on transwells

home_icon4

GI Toxicity

Screen compounds for 
drug-induced GI toxicity early

home_icon3

Intestinal Drug Disposition

Developed to replace Caco-2 cells (cancer cells) and animals

NEWS AND ARTICLES

November 4, 2021

Webinar: Studying the Responses to Cytokines Using Novel In Vitro Stem Cell Platforms

Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin, Ph.D, Chief Scientific Officer, Altis Biosystems discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.    

Watch Video

August 5, 2021

The Power Of RepliGut® In Vitro Intestinal Stem Cell Models

Both current in vitro and in vivo models used in the development of candidate therapies for the treatment of intestinal diseases have severe limitations. RepliGut®, an in vitro human intestinal epithelial stem cell model, addresses many of these issues and has significant potential to reduce the time and cost of drug development. This model may even help to identify optimal therapies for individual patients.

Read More

DIGITAL EVENTS

CONTACT US

Have a question? Want to stay informed about Altis, RepliGut, and more platforms currently under development? Send us a message!